DOACs: apixaban, rivaroxaban, edoxaban, dabigatran

Direct oral anticoagulant (DOAC) planning balances procedural bleeding risk against the consequences of interruption. The exact medicine, dose, renal function and intended anaesthetic technique all matter.

Interruption before the procedure

For many elective procedures, published protocols use approximately 1 day of interruption for apixaban, rivaroxaban or edoxaban before low-to-moderate bleeding-risk surgery and 2 days before higher-risk surgery. Dabigatran commonly needs 1–4 days, depending particularly on renal function. Renal impairment and other clinical factors can require a different interval. These are examples of surgical protocols, not neuraxial instructions or a patient-specific timetable. CHEST 2022 generally advises against heparin bridging during DOAC interruption.

Some minimal bleeding-risk procedures may be performed with continued or minimally interrupted DOAC therapy, according to the guideline and local practice.

Restarting treatment

Resumption depends on adequate haemostasis, the procedure and postoperative bleeding risk. Common elective protocols allow around 24 hours after lower-risk procedures and 48–72 hours after higher-risk procedures, with later resumption when clinical circumstances require it. Interim thromboprophylaxis is a separate, individual decision and is not equivalent to routine therapeutic bridging.

Regional anaesthesia

Surgical bleeding-risk intervals do not establish timing for neuraxial or deep plexus/peripheral blocks. Those procedures require separate consideration of the ASRA fifth-edition recommendations.

ASRA distinguishes low-dose from high-dose regimens and considers the drug and renal function. A single interruption or restart interval cannot safely represent every regimen.

Before a block: the relevant drug-and-dose recommendation covers the interval after the last dose and any circumstances in which a validated laboratory assessment may be useful.
Laboratory assessment: a drug concentration in ng/mL and anti-Xa activity in IU/mL are different measurements. Assay calibration, sensitivity and interpretation matter; laboratory advice is needed before applying a guideline threshold. This summary does not treat every anti-Xa test as interchangeable or rule out all heparin-calibrated assays.
Renal function is particularly important for dabigatran and may also affect planning for factor Xa inhibitors.
After a block: needle placement and catheter removal have regimen-specific relationships to the first postoperative dose. The complete recommendation is needed for the exact medicine and dose; a universal 24-hour rule is not appropriate.
Reversal is a separate specialist decision for situations such as serious bleeding or urgent surgery. It is not a routine shortcut to make a neuraxial procedure possible.

The linked guideline provides the full drug-and-dose recommendations, exceptions and evidence grades. This page is an overview rather than a neuraxial timing chart.

Practical application

A record of the exact drug, dose, indication and last dose time supports an individual plan.
Assessment of creatinine clearance helps identify whether the selected protocol applies, particularly with dabigatran.
The procedure’s bleeding risk and any planned neuraxial or deep block can be documented together.
Written dates and times for interruption, reassessment and planned resumption can reduce misunderstanding.
CHEST 2022 suggests against routine DOAC coagulation testing to guide perioperative management.

Urgent surgery

Urgent surgery in patients who have recently taken a DOAC requires assessment of time since last dose, renal function and bleeding risk. Specific reversal agents and their availability vary by setting. Local haematology protocols should guide their use.